1. Medtech Insight
  2. >>Policy & Regulation

New CMS Lab Test Panel Meets To Make Payment Policy Recommendations

The Medicare Advisory Panel on Clinical Diagnostic Laboratory Tests held its inaugural meeting Aug. 26 to begin work on recommending crosswalks and gapfills for more than 25 molecular tests codes.

Members of the new CMS Clinical Diagnostic Laboratory Test Advisory Panel argued that both algorithm and bioinformatics portions of genomic-sequenced tests deserve appropriate reimbursement during the group's inaugural meeting in Baltimore on Aug. 26. The panel recommended Medicare payment codes for more than 25 molecular tests at the gathering.

The panel was set up under the provisions of the Protecting Access to Medicare Act, signed into law April 1, 2014

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Policy & Regulation

More from Medtech Insight

Dexcom Puts Stelo On Amazon, Setting Up Consumer Showdown With Abbott

 
• By Shubham Singh

In addition to broader distribution, Dexcom is investing heavily in software enhancements for Stelo. The 180-day data lookback feature is just one of several planned upgrades intended to improve personalization and user engagement.

Subsense Develops Nonsurgical, Nanoparticle-Based Brain-Computer Interface For Neurological Disorders

 
• By Marion Webb

Neurotechnology start-up Subsense came out of stealth with $17m in seed funding to develop a nonsurgical, nanoparticle-based brain-computer interface. Medtech Insight spoke with the firm’s new neurotech lead Cyril Eleftheriou about the technology and its potentially wide applications for treating Parkinson’s, epilepsy, inner speech decoding, and more.

Does Makary’s Reorg Choice Mark FDA Turning Point?

 
• By Michael McCaughan

US FDA Commissioner Martin Makary’s disavowal of a proposed reorganization plan may be an important turning point in the Trump Administration. The move does not improve the situation, but may mean the administration stops actively making things worse.